Sanofi Archives

News and Trends 5 Sep 2015

Genzyme pays another $32.5M for cheating on one of its product’s supposed applications

Genzyme’s $22.28M (€20M) penalty wasn’t enough for the US Department of Justice to resolve its criminal marketing of Seprafilm. Sanofi’s biotech subsidiary will therefore have to pay another $32.5M (€29,2M) to avoid further legal implications. Criminal charges caught Cambridge-based Genzyme by promoting its tape-like Seprafilm for wrong allegations between 2005 and 2010, up until one year […]

September 5, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Sep 2015

Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

Paris based Sanofi has pulled out of a €176M deal with Californian clinical stage biotech Ardelyx. A licensing deal for a program of pre-clinical candidates treating renal diseases and IBS-C, similar to Tenapanor, was revoked. In February 2015, Fresno County’s Ardelyx announced its pharma-baby, Tenapanor, had passed its stage IIB clinical trials in successfully reducing serum levels of phosphate. […]

September 2, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 1 Sep 2015

Does your business plan need some enhancement? The Science4Life Venture Cup 2016 kicks off today!

The application for Germany’s Science4Life Venture Cup 2016 is now open! Join the competition to meet sector-specific experts, benefit from the experiences of former participants and win up to €25k to help your startup to get to the next level. Labiotech knows from its own experience that an aspiring startup needs a convincing business plan […]

September 1, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 31 Aug 2015

When Tech and Biotech merge, Google and Sanofi partner up to revolutionize Diabetes Management

Taking care of diabetes is still far too complex currently. In future, Sanofi and Google will jointly take care of this problem, hoping to ease the life of millions of people with type 1 and type 2 diabetes. When it comes to transforming our diabetes treatment technology, Google loves European Pharmas. Together with Novartis, it […]

August 31, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 28 Aug 2015

[Update] Valneva’s duck stem cells attract two new Vaccine-deals

French Valneva continues to sign license agreements for its duck derived stem cell line that produces novel vaccines. Lyon-based Valneva was formed from the 70-year old duck breeder Group Grimaud. It entered the biotech scene in 2000 as Vivalis and today is on Euronext-Paris and the Vienna stock exchange, has a market cap of about €275M […]

August 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

Evotec enters Immuno-Oncology and Diabetes Therapy with Help from Sanofi

Evotec had to announce a setback recently when its Alzheimer’s treatment in collaboration with Roche failed in Phase IIb. However, another strong partner on its side, Sanofi, never lost trust in the German biotech’s value. In the last three days, the French giant entered into two new projects with Evotec, which target diabetes and immuno-oncology. […]

August 10, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 3 Aug 2015

Sanofi’s CEO, Olivier Brandicourt takes stock of its Biotech pipeline

Olivier Brandicourt, new CEO of Sanofi since last April, has been interviewed by EuroBusiness Media on the company’s last results. The successor of Chris Viehbacher took the opportunity to show the good results made by its Biotech pipeline. Genzyme, the rare diseases arm of Sanofi, was an important growth driver again this quarter. Total sales of the Rare […]

August 3, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 28 Jul 2015

Struggling AstraZeneca sells Rare Disease drug to Genzyme-Sanofi for €300M

The Pharma giant AstraZeneca is still struggling even if in better shape. It just sold one of his rare disease drug already on the market to THE rare disease Biotech Genzyme, now part of Sanofi. AstraZeneca is under pressure. Last April 2015, the company reported a fall in revenues and profits (7% lower than previous […]

July 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 27 Jul 2015

Hunt for Hypercholesterolemia Drug Approval: Sanofi vs Amgen vs Pfizer

Cardiovascular diseases kill around 2.6 million people each year and embody one of the biggest healthcare markets in the World. Not surprising to see Big Pharmas/Biotechs overactive in this field. What are their plans? Today, Sanofi‘s hypercholesterolemia therapy Praluent was recommended to the European market. It is a fully human monoclonal antibody developed in collaboration with the American Big Biotech Regeneron. But Amgen announced […]

July 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 16 Jul 2015

Sanofi’s Extreme Makeover gives prominence to Genzyme

There seems to be a tendency towards revolution amongst Sanofi’s CEOs. Olivier Brandicourt, Managing director of the French drugmaker since his €4.1M golden handshake with the company, has come up with a restructuration plan that will reduce Sanofi’s business units from seven to five. The French businessman expects this reorganization will help the company to […]

July 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Jul 2015

Sanofi to solve Growing Resistance against Malarial Treatments

Sanofi extended its collaboration with Medicines for Malaria Venture (MMV) to jointly develop a new combination therapy against malaria, the deadliest parasitic disease worldwide. The difficult access and the fear of a growing resistance to the existing treatments highlight the importance of this partnership. Atemisinin-based combination therapies (ACT) are at this moment the most efficient […]

July 10, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 31 May 2015

Who are the European Cancer Champions?

Cancer makes no difference… Children, elderly, healthy, disabled, black, white, etc… the disease randomly selects its targets. One of the biggest challenges of the Biotech industry today, is to lead groundbreaking innovations capable of treating cancer, which also encompass each individual’s biological specificity. So who are the leading champions? Recently, Thomson Reuters listed the 5 […]

May 31, 2015 - 2 minutesmins - By Alexandre Lowrey

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us